Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MRK
STRONG BUYAPPROVEMerck & Co., Inc. · Healthcare · United States · $323.7B · Avg Vol: $1.4B/d
This is the US line of Merck, which combines a dominant oncology franchise with a strong animal-health and vaccines business, generating large free cash flow supporting a growing dividend and buybacks, with strong momentum (M80). Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
Merck & Co., Inc. is a leading global pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medicines, vaccines, and animal health products. With a robust R&D pipeline and blockbuster franchises like Keytruda in oncology, Merck maintains a formidable global market presence, addressing significant medical needs across various therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.3B | 60.1B | 64.2B | 65.0B | 3.1% | 65.8B | 66.9B | 70.1B | 3.9% |
| EPS | 5.73 | 0.14 | 6.77 | 7.38 | 8.8% | 3.46 | 2.74 | 9.66 | 14.4% |
| Shares | 2.5B | 2.5B | 2.5B | 2.5B | -2.5% | 2.5B | — | — | — |
| Debt | 30.7B | 35.1B | 37.1B | 49.3B | 17.1% | 49.1B | — | — | — |
| Equity | 46.0B | 37.6B | 46.3B | 52.6B | 4.6% | — | — | — | — |
| Op CF | 19.1B | 13.0B | 21.5B | 16.5B | -4.8% | 17.9B | — | — | — |
| Inv CF | -5.0B | -14.1B | -7.7B | -13.7B | — | — | — | — | — |
| Fin CF | -9.1B | -4.8B | -7.0B | -1.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MRK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MRK | Merck & Co., Inc.(you) | $323.7B | 92 | STRONG BUY |
| RO.SW | Roche Holding AG | $336.1B | 92 | STRONG BUY |
| NVS | Novartis AG | $294.6B | 91 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 91 | STRONG BUY |
| 4AB.DE | AbbVie Inc. | $438.1B | 87 | STRONG BUY |
| AMG.DE | Amgen Inc. | $194.3B | 90 | STRONG BUY |
| AZN | AstraZeneca PLC | $262.5B | 83 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $160.5B | 92 | STRONG BUY |
| JNJ.MX | Johnson & Johnson | $588.5B | 88 | STRONG BUY |
| PFE.DE | Pfizer Inc. | $138.0B | 94 | STRONG BUY |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.0%